O	0	10	Prevention
O	11	13	of
O	14	28	postmenopausal
B-condition	29	41	osteoporosis
O	42	44	in
B-ethinicity	45	52	Chinese
O	53	58	women
O	58	59	:
O	60	61	a
O	62	63	5
O	63	64	-
O	64	68	year
O	68	69	,
O	70	76	double
O	76	77	-
O	77	82	blind
O	82	83	,
O	84	94	randomized
O	94	95	,
O	96	104	parallel
O	105	112	placebo
O	112	113	-
O	113	123	controlled
O	124	129	study
O	129	130	.

O	131	133	To
O	134	141	observe
O	142	145	the
O	146	159	effectiveness
O	160	163	and
O	164	170	safety
O	171	173	of
O	174	183	menopause
O	183	184	-
O	184	191	related
O	192	199	hormone
O	200	207	therapy
O	208	209	(
O	209	212	MHT
O	212	213	)
O	214	216	to
O	217	224	prevent
O	225	229	bone
O	230	234	loss
O	235	237	in
O	238	245	Chinese
O	246	251	women
O	252	258	during
O	259	262	the
O	263	273	menopausal
O	274	284	transition
O	285	288	and
O	289	294	early
O	295	304	menopause
O	304	305	,
O	306	308	as
O	309	313	well
O	314	316	as
O	317	319	to
O	320	328	evaluate
O	329	332	the
O	333	340	effects
O	341	343	of
O	344	345	5
O	345	346	-
O	346	350	year
O	351	354	MHT
O	355	357	on
O	358	365	overall
O	366	372	health
O	373	375	to
O	376	379	add
O	380	385	Level
O	386	387	I
O	388	396	evidence
O	397	400	for
O	401	404	the
O	405	415	prevention
O	416	418	of
O	419	431	osteoporosis
O	432	437	using
O	438	441	MHT
O	441	442	.

O	443	447	This
O	448	456	clinical
O	457	462	study
O	463	466	was
O	467	468	a
O	469	480	prospective
O	480	481	,
O	482	488	double
O	488	489	-
O	489	494	blind
O	494	495	,
O	496	506	randomized
O	506	507	,
O	508	516	parallel
O	517	524	placebo
O	524	525	-
O	525	535	controlled
O	536	541	study
O	541	542	.

B-eligibility	543	550	Chinese
I-eligibility	551	556	women
I-eligibility	557	559	in
I-eligibility	560	563	the
I-eligibility	564	574	menopausal
I-eligibility	575	585	transition
I-eligibility	586	589	and
I-eligibility	590	595	early
I-eligibility	596	605	menopause
O	606	610	were
O	611	619	randomly
O	620	629	allocated
O	630	632	to
O	633	636	the
B-intervention	637	640	MHT
I-intervention	641	646	group
O	647	649	or
O	650	653	the
B-control	654	661	placebo
I-control	662	667	group
O	667	668	.

O	669	672	All
O	673	681	subjects
O	682	690	received
O	691	692	a
O	693	694	5
O	694	695	-
O	695	699	year
O	700	712	intervention
O	712	713	.

O	714	717	The
O	718	731	effectiveness
O	732	734	of
O	735	738	MHT
O	739	742	for
O	743	747	bone
O	748	755	mineral
O	756	763	density
O	764	765	(
O	765	768	BMD
O	768	769	)
O	770	773	and
O	774	778	bone
O	779	789	metabolism
O	790	793	and
O	794	797	the
O	798	804	safety
O	805	807	of
O	808	811	MHT
O	812	814	in
O	815	823	relation
O	824	826	to
O	827	837	glycolipid
O	838	848	metabolism
O	848	849	,
O	850	856	breast
O	857	863	cancer
O	863	864	,
O	865	868	and
O	869	883	cardiovascular
O	884	891	disease
O	892	896	were
O	897	904	studied
O	904	905	.

O	906	908	In
O	909	912	the
O	913	916	MHT
O	917	922	group
O	922	923	,
O	924	929	women
O	930	932	in
O	933	937	both
O	938	948	transition
O	949	952	and
O	953	958	early
O	959	968	menopause
O	969	975	showed
O	976	977	a
O	978	989	significant
O	990	998	increase
O	999	1001	in
B-outcome	1002	1008	lumbar
I-outcome	1009	1012	and
I-outcome	1013	1020	femoral
I-outcome	1021	1025	neck
I-outcome	1026	1029	BMD
O	1030	1035	after
O	1036	1039	the
O	1040	1043	1st
O	1044	1048	year
O	1049	1051	of
O	1052	1059	therapy
O	1059	1060	;
O	1061	1064	BMD
O	1065	1071	tended
O	1072	1074	to
O	1075	1083	decrease
O	1084	1086	in
O	1087	1090	the
O	1091	1094	3rd
O	1095	1099	year
O	1100	1103	but
O	1104	1114	ultimately
O	1115	1118	was
O	1119	1128	sustained
O	1129	1131	at
O	1132	1138	stable
O	1139	1145	levels
O	1146	1150	that
O	1151	1155	were
O	1156	1160	near
O	1161	1164	the
O	1165	1173	baseline
O	1174	1180	levels
O	1180	1181	.

O	1182	1184	In
O	1185	1188	the
O	1189	1196	placebo
O	1197	1202	group
O	1202	1203	,
B-outcome	1204	1207	BMD
O	1208	1217	decreased
O	1218	1220	at
O	1221	1225	both
O	1226	1231	sites
O	1231	1232	.

B-outcome	1233	1243	Metabolism
I-outcome	1244	1251	indexes
I-outcome	1252	1255	and
I-outcome	1256	1262	breast
I-outcome	1263	1273	ultrasound
I-outcome	1274	1285	examination
O	1286	1294	findings
O	1295	1298	did
O	1299	1302	not
O	1303	1309	differ
O	1310	1323	significantly
O	1324	1331	between
O	1332	1335	the
O	1336	1339	MHT
O	1340	1343	and
O	1344	1351	placebo
O	1352	1358	groups
O	1358	1359	.

O	1360	1365	Three
O	1366	1371	cases
O	1372	1374	of
B-outcome	1375	1381	breast
I-outcome	1382	1388	cancer
O	1389	1392	and
O	1393	1398	three
O	1399	1404	cases
O	1405	1407	of
B-outcome	1408	1422	cardiovascular
I-outcome	1423	1430	disease
O	1431	1435	were
O	1436	1445	diagnosed
O	1446	1452	during
O	1453	1459	follow
O	1459	1460	-
O	1460	1462	up
O	1462	1463	.

B-iv-bin-abs	1464	1467	One
B-outcome	1468	1474	breast
I-outcome	1475	1481	cancer
O	1482	1486	case
O	1487	1490	and
B-iv-bin-abs	1491	1494	two
B-outcome	1495	1509	cardiovascular
I-outcome	1510	1517	disease
I-outcome	1518	1523	cases
O	1524	1532	occurred
O	1533	1535	in
O	1536	1539	the
O	1540	1543	MHT
O	1544	1549	group
O	1549	1550	.

O	1551	1555	Five
O	1555	1556	-
O	1556	1560	year
O	1561	1571	sequential
O	1572	1579	therapy
O	1580	1584	with
O	1585	1593	estrogen
O	1594	1597	and
O	1598	1610	progesterone
O	1611	1614	can
O	1615	1623	increase
O	1624	1626	or
O	1627	1635	maintain
O	1636	1639	the
O	1640	1643	BMD
O	1644	1646	of
O	1647	1652	women
O	1653	1655	in
O	1656	1661	their
O	1662	1672	menopausal
O	1673	1683	transition
O	1684	1687	and
O	1688	1693	early
O	1694	1703	menopause
O	1703	1704	.

O	1705	1709	This
O	1710	1717	regimen
O	1718	1721	had
O	1722	1724	no
O	1725	1733	negative
O	1734	1740	effect
O	1741	1743	on
O	1744	1754	glycolipid
O	1755	1765	metabolism
O	1766	1769	and
O	1770	1773	did
O	1774	1777	not
O	1778	1786	increase
O	1787	1790	the
O	1791	1795	risk
O	1796	1798	of
O	1799	1805	breast
O	1806	1812	cancer
O	1813	1815	or
O	1816	1830	cardiovascular
O	1831	1837	events
O	1837	1838	.
